Healthcare - Industry centre - Yahoo Finance
- NVSAmerican City Business Journals•20 minutes ago
Akcea Therapeutics, a Cambridge-based subsidiary of Ionis Pharmaceuticals developing treatments for lipid disorders, said Monday that it plans to raise up to $100 million in an initial public offering. The 26-employee company said in a federal filing that it had applied to list its stock on the Nasdaq under the symbol “AKCA.” It would be the second Massachusetts-based biotech to go public so far in 2017, after Cambridge cancer drug developer Jounce Therapeutics (JNCE). A $100 million IPO would also be one of the largest offerings for a local biotech in recent memory.